Shupeng Zou

Dr. Shupeng Zou

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 December 2023 in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
Verified
Journal Article
Closed access
SZShupeng Zou
Shupeng Zou
MOMengling Ouyang
Mengling Ouyang
QCQian Cheng
Qian Cheng
XSXuan Shi
Xuan Shi
HSHui Ming Sun
Hui Ming Sun

1 September 2019 in Revista Brasileira de Farmacognosia
Verified
Journal Article
Open access
SZShupeng Zou
Shupeng Zou
YWYafen Wang
Yafen Wang
Qun ZhouQun Zhou
Qun Zhou
YLYuanyuan Lu
Yuanyuan Lu
YZYonghui Zhang
Yonghui Zhang
JZJinwen Zhang
Jinwen Zhang

16 December 2022 in World Journal of Clinical Cases
Verified
Journal Article
Open access
SZShupeng Zou
Shupeng Zou
QCQian Cheng
Qian Cheng
CFCheng-Yang Feng
Cheng-Yang Feng
CXChan Xu
Chan Xu
MSMing-Hui Sun
Ming-Hui Sun
As a first-line treatment regimen for Helicobacter pylori (H. pylori) infection, antibiotic therapy is widely used worldwide. However, the question of increasing antibiotic resistance must be considered. Given this issue, we need to find ways to reduce drug resistance. This study examined all currently available first-line regimens and compared them with standard triple treatment through a network meta-analysis of randomized controlled trials (RCTs). To compare first-line treatment regimens for eradication of antibiotic-resistant H. pylori strains. To compare the effectiveness of the first-line regimens for treating H. pylori infection, a Bayesian network meta-analysis was applied to process data extracted from RCTs. The plausible ranking for each regimen was assessed by the surface under the cumulative ranking curve (SUCRA). In addition, we conducted a relevant search by reference citation analysis. Twenty-five RCTs involving 12029 participants [including 1602 infected with clarithromycin (CAM)-resistant strains and 1716 infected with metronidazole (MNZ)-resistant strains] were included, in which a total of seven regimens were used for H. pylori eradication. The results showed that dual therapy containing a high-dose proton pump inhibitor (HDDT) [odds ratio (OR): 4.20, 95% confidence interval (CI): 2.29-8.13] was superior to other therapies for all patients, including those with CAM/MNZ-resistant H. pylori infection. In the comparative effectiveness ranking, for CAM-resistant H. pylori, HDDT (OR: 96.80, 95%CI: 22.46-521.9) had the best results, whereas standard triple therapy ranked last (SUCRA: 98.7% vs 0.3%). In the subgroup of high cure rates (≥ 90%), HDDT was also generally better than other therapies. For the eradication of CAM- and MNZ-resistant H. pylori strains, HDDT exhibited considerable advantages. The studies of CAM-resistant H. pylori were based on small samples due to a lack of antibiotic sensitivity tests in many RCTs, but the results showed that all patients, including those with CAM-resistant H. pylori infection, had a concordant trend. Overall, HDDT may be a reference for RCTs and other studies of H. pylori eradication.

2 November 2023 in Journal of Clinical Pharmacy and Therapeutics
Verified
Journal Article
Open access
PDF file
YZYazheng Zhao
Yazheng Zhao
QCQian Cheng
Qian Cheng
SZShupeng Zou
Shupeng Zou
XSXuan Shi
Xuan Shi
MOMengling Ouyang
Mengling Ouyang
HSHui Ming Sun
Hui Ming Sun
Objectives. To investigate adverse events (AEs) associated with upadacitinib in the real world using data mining from the FDA Adverse Event Reporting System (FAERS). Methods. Disproportionality analysis, including the reporting odds ratio (ROR), the proportional reporting ratio (PRR), the Bayesian confidence propagation neural network (BCPNN), and the multiitem gamma Poisson shrinker (MGPS) algorithms, was used to quantify the signals of upadacitinib-associated AEs. Results. The study found 23683 reports of AEs associated with upadacitinib. A total of 149 substantial disproportionality preferred terms (PTs) that complied with all algorithms were identified. The infections discovered matched those mentioned in the specification and clinical trials, including pneumonia, upper respiratory tract infection, herpes zoster, and acne. Malignant and thrombotic AEs were also noted. Diverticulitis, myocardial infarction, transient ischaemic attack, and dysstasia were among the new AEs found. Upadacitinib-related AEs had a median onset time of 237days and an interquartile range (IQR) of 78509days. Conclusions. The findings of our study were in line with clinical observations, and we also identified potential novel and unexpected AEs signals for upadacitinib, indicating the necessity for prospective clinical trials to corroborate these findings and demonstrate their link. Our results offered significant support for additional upadacitinib safety research.